Search research articles
Contact Us
Filters
Showing results (21-30 of 83) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2013
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, et al.
Advances in Therapy
|
March 15, 2011
First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor
François Lefrère, Anne-Colette Brignier, Caroline Elie, et al.
Blood
|
June 22, 2012
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
Richard Delarue, Corinne Haioun, Vincent Ribrag, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
October 20, 2009
Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation
David Ghez, Amédée Renand, Yves Lepelletier, et al.
Plos One
|
July 23, 2009
Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases
Danielle Canioni, Bénédicte Deau-Fischer, Pierre Taupin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 26, 2019
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Carmelo Carlo-Stella, Richard Delarue, Lydia Scarfo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study
Alexandre Morel, Josette Brière, Laurence Lamant, et al.
Blood
|
September 17, 2014
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
Céline Bossard, Maria Pamela Dobay, Marie Parrens, et al.
Current Medical Research and Opinion
|
October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial
Judith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Transfusion
|
June 22, 2002
High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose
François Lefrère, Richard Delarue, Dominique Somme, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 83) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 2013
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, et al.
Advances in Therapy
|
March 15, 2011
First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor
François Lefrère, Anne-Colette Brignier, Caroline Elie, et al.
Blood
|
June 22, 2012
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
Richard Delarue, Corinne Haioun, Vincent Ribrag, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|
October 20, 2009
Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation
David Ghez, Amédée Renand, Yves Lepelletier, et al.
Plos One
|
July 23, 2009
Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases
Danielle Canioni, Bénédicte Deau-Fischer, Pierre Taupin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 26, 2019
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Carmelo Carlo-Stella, Richard Delarue, Lydia Scarfo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study
Alexandre Morel, Josette Brière, Laurence Lamant, et al.
Blood
|
September 17, 2014
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
Céline Bossard, Maria Pamela Dobay, Marie Parrens, et al.
Current Medical Research and Opinion
|
October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial
Judith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Transfusion
|
June 22, 2002
High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose
François Lefrère, Richard Delarue, Dominique Somme, et al.
Page
of 9